Immune system’s B cells appear to influence how heart develops, beats
New research in mice suggests that certain immune cells may help guide fetal development of the heart and play a role in how the adult heart beats, according to new research at Washington University School of Medicine in St. Louis.
The findings, published in the journal JCI Insight, may help lay a foundation for immunotherapies that target forms of heart disease.
“This behavior of the immune system B cells has not been described before,” said first author Luigi Adamo, MD, PhD, an instructor in medicine. “There appears to be some type of interaction between these B cells and the inner lining of the heart’s blood vessels. Our study sets the stage to start developing B cell-targeted therapies for various forms of heart disease.”
B cells are a type of white blood cell well-known for their role as sentinels that circulate in the bloodstream and manufacture antibodies to fight off infection. As such, they are not thought to be present in healthy tissues.
Focusing on B cells that appear to hang out in the heart, Adamo and his colleagues were surprised to find that these cells neither freely circulate through the body’s blood vessels nor reside permanently in the heart muscle. Rather, these particular B cells were found lingering in the small blood vessels that feed oxygen and nutrients to the heart muscle.
“Because they were in the blood vessels, it was conceivable that they were only a random sample of circulating B cells,” he said. “But when we compared their active genes to those of freely circulating B cells, we found that there was something special about them: This is a type of circulating B cell that arrives in the heart vasculature and becomes sticky.”
These sticky B cells still circulate through the heart, the blood and spleen, according to the researchers, but they slow down considerably, taking their time as they transit through the heart vasculature.
“We’re still working to understand why,” Adamo said. “But what was even more surprising was what happened when we removed B cells from the mice.”
When the researchers — led by senior author Douglas L. Mann, MD, the Tobias and Hortense Lewin Distinguished Professor of Cardiovascular Diseases and director of the university’s Cardiovascular Division — analyzed genetically modified mice that lacked B cells, the scientists found that their hearts were smaller and contracted differently than the hearts of normal mice.
The hearts of mice missing B cells relaxed faster and pushed more blood out of the left ventricle with each beat. The scientists also found that in such mice, the number of T cells, a different type of immune cell, doubled in the heart.
“We are working on more studies to learn if the missing B cells have a direct effect on the structure and rhythm of the heart, or if we are seeing some indirect effect during development or through the change in T cells,” Adamo said. “But that removing B cells had any effect on the heart is completely unexpected.”
Adamo said the study raises the possibility that this type of slowly traveling B cell is present and having an effect in other organs. Further, the findings open the door to possible immunotherapies to protect the heart and other organs that might also see this B cell behavior, according to the researchers.
“A small number of recent studies, including one of ours, suggest B cells play a role in heart failure, so it is an up-and-coming field,” Adamo said.
This study was supported by the National Institutes of Health (NIH), grant numbers R01 HL-58081, HL-73017-0, HL-089543-01, HL 111094, R00 HL138163, T32 HL007081, S10OD020136 and 1K08HL145108-01A1; the Center for Cardiovascular Research at Washington University School of Medicine; and a pilot grant from the McDonnell Genome Institute at Washington University. Additional support was provided by the Washington University Digestive Disease Research Center Morphology Core, which is funded by the National Institute of Diabetes and Digestive and Kidney Diseases, grant number P30 DK052574; the Washington University Flow Cytometry & Fluorescence Activated Cell Sorting Core; and the Institute of Clinical and Translational Sciences at Washington University, CTSA grant number UL1 TR002345.
Adamo and Mann are co-founders of a startup company focused on the development of B cell modulating therapies for the treatment of heart failure and are co-inventors on a related patent owned by Washington University.
Adamo L, Rocha-Resende C, Lin C, Evans S, Williams J, Dun H, Li W, Mpoy C, Andhey PS, Rogers BE, Lavine K, Kreisel D, Artyomov M, Randolph GJ, Mann DL. Myocardial B cells are a subset of circulating lymphocytes with delayed transit through the heart. JCI Insight. Feb. 13, 2020.
Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.